Release no. 7, 2011

Copenhagen and Oslo, 27th April 2011, 2011-04-27 16:26 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
today that the Company has signed a sponsored research agreement with Dr. Rolf
Brekken at the University of Texas Southwestern Medical Center, Dallas, USA to
further understand the mechanism and potential differentiation of Affitech's
lead antibody drug candidate AT001/r84.

Affitech's Chief Scientific Officer, Dr. Alexander Duncan, said: - We are
delighted to have attracted the interest and participation of an outstanding
investigator at the forefront of cancer research. Rolf is at the leading edge
of understanding cancer biology and will be a huge asset to our anti-cancer
programs. Rolf and UT Southwestern have been involved since the start of the
AT001/r84 story and their continued participation and involvement in
understanding angiogenesis and therapeutic intervention, immune competence and
mechanisms of resistance will enhance and extend our clinical program. This
research agreement with a leading investigator at a world-renowned cancer
centre extends our capabilities to advance our lead therapeutic program
AT001/r84, an anti-VEGF antibody, significantly.

Dr. Rolf Brekken, associate professor of surgical oncology and pharmacology at
UT Southwestern, said: - We already have an existing relationship with
Affitech, having previously studied their product candidate AT001/r84 in mouse
models. Continuing this scientific relationship with Affitech will allow us to
lead AT001/r84 through more detailed studies examining combination therapies
and mechanisms of drug resistance in our labs here in Texas.

The University of Texas Southwestern Medical Center in Dallas in the USA will
conduct certain research regarding Affitech's anti-VEGF antibody drug candidate
AT001/r84, including certain comparative studies with bevacizumab in animal
models. Affitech will collaborate with Dr. Rolf Brekken, who has previously
published scientific articles on AT001/r84's effect on cancer in mice.

Affitech will obtain certain rights to intellectual property developed during
the course of the research with a view to profitable commercialization of such
intellectual property for Affitech's benefit. The university will perform the
research and grant certain rights to such intellectual property.


About Affitech

Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
candidates AT001/r84 and AT008/CCR4 with Russian partner NauchTekhStroy Plus.
Further information is available at www.affitech.com.


Disclaimer This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact
on results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.


No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient of this news release by
virtue of the information contained herein.





Contact:

Randi Krogsgaard, Director IR & Corporate Communications

Tel # +45 2320 1001, e-mail: [email protected]